Wednesday Morning’s Market Insights: Netflix Inc. (NFLX), Conatus Pharmaceuticals Inc (CNAT), Valeant Pharmaceuticals Intl Inc (VRX), Mobileye NV (MBLY)


Netflix, Inc. (NASDAQ:NFLX) is down 2.43% in premarket trading to $105.04 as all the FANG stops are dropping in 2016. FANG, or Facebook, Amazon, Netflix, and Google all drastically outperformed the S&P in 2015, but are all off to rough starts in 2016. Netflix has already fallen 5.88% in 2016, compared to the 135% boost experienced in 2015. According to analysts polled by TipRanks in the last 3 months, 17 are bullish on the video streaming company, 2 are bearish, and 6 remain on the sidelines. The average 12-month price target between these 25 analysts is $126.04, marking a 17% potential upside from where shares last closed.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) is soaring 30% in pre-market trading after the company announced yesterday it achieved positive initial phase 2 results with drug Emricasan, intended to treat liver cirrhosis. The study displayed a significant reduction in levels of cCK19, a protein fragment present in elevated levels in patients with the disease. According to TipRanks’ statistics, 2 analysts rated the company in the past 3 months, both with a Buy rating. The average 12-month price target for the stock is $7.50, marking a 161% upside from where shares last closed.

CNAT Consensus

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is down over 6% in pre-market trading after the Wall Street Journal announced yesterday after market close that the company plans on appointing a new CEO to take Pearson’s place while he remains in the hospital with pnemonia. The company has a few candidates lined up for the position, including former CFO Howard Schiller. The company now faces the decision of who will speak at JPMorgan Chase & Co. health-care industry investor conference next week. According to TipRanks’ statistics, out of the 22 analysts who have rated the company in the past 3 months, 13 gave a Buy rating, 1 gave a Sell rating, while 8 remain on the sidelines.

VRX Consensus

Mobileye NV (NYSE:MBLY) is up 6.42% in pre-market trading after the company announced it is developing Road Experience Management; a crowd-sourced technology that will employ real-time data to support autonomous driving. General Motors, Mobileye’s largest customer, is engaged in this project. The project will add onto Mobileye’s existing technology that recognizes landmarks on the roadway to enable autonomous driving. Mobileye expects the new technology to achieve GPS accuracy within a 10 centimeter range, compared to today’s GPS, which has a localization accuracy of about 10 meters. According to TipRanks, 4 analysts are bullish on Mobileye while 1 remains neutral. The average 12-month price target for the stock is $65.38, marking a 81% potential upside from where shares last closed.

MBLY Consensus